Business
Aytu BioScience Announces Acceptance of Natesto Spermatogenesis Study Results for Presentation at ENDO 2020
ENGLEWOOD, CO / ACCESSWIRE / January 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"ENGLEWOOD, CO / ACCESSWIRE / January 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs today announced the acceptance of a scientific abstract reporting the results of the Natesto Spermatogenesis Study by the Endocrine Society for presentation at the Endocrine Society's Annual Meeting.Thomas Masterson, MD, Urology Fellow in the Department of Urology at the University of Miami School of Medicine, will present the Natesto clinical study results during a poster session at ENDO 2020, which will be held in San Francisco, CA March 28-31, 2020.The Natesto Spermatogenesis Study has been conducted under the direction of principal investigator Ranjith Ramasamy, MD, Associate Professor and Director of Reproductive Urology, Department of Urology, University of Miami School of Medicine.Presentation Details:Presenting Author: Thomas Masterson, MD, Fellow, Department of Urology, University of Miami School of MedicinePresentation Title: The Effect of Natesto on Spermatogenesis, Reproductive Hormones, and Hypogonadal Symptoms: A Phase IV StudyAbstract Number: 5238Additionally, Dr. Masterson has been selected to receive an Outstanding Abstract Award in conjunction with ENDO 2020 for this abstract.All abstracts presented at ENDO 2020 will be published after the conclusion of ENDO 2020 in the Journal of the Endocrine Society.About Aytu BioScience, Inc.Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or \"Low T\"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension in...